Clinical case of lung spindle cell carcinoma markedly responsive to pembrolizumab

Clinical case of lung spindle cell carcinoma markedly responsive to pembrolizumab

Abstract A 52‐year‐old man underwent pneumonectomy of the left lung for previously diagnosed primary spindle cell carcinoma (pT4aN1M0, stage III B) with programmed death‐ligand 1 expression (tumor proportion score ≥95%) and without epidermal growth factor receptor gene mutation and anaplastic lympho...

Full description

Bibliographic Details
Main Authors: Yoshiko Mizushina, Fumiyoshi Ohyanagi, Jun Shiihara, Motoko Nomura, Hiromitsu Ohta, Hisashi Oshiro, Hiroyoshi Tsubochi, Gen Kusaka, Yasuhiro Yamaguchi
Format: Article
Language:English
Published: Wiley 2021-08-01
Series:Thoracic Cancer
Subjects:
immune checkpoint inhibitor
lung cancer
pembrolizumab
pseudoprogression
spindle cell carcinoma
Online Access:https://doi.org/10.1111/1759-7714.14068
Description
Summary:Abstract A 52‐year‐old man underwent pneumonectomy of the left lung for previously diagnosed primary spindle cell carcinoma (pT4aN1M0, stage III B) with programmed death‐ligand 1 expression (tumor proportion score ≥95%) and without epidermal growth factor receptor gene mutation and anaplastic lymphoma kinase fusion gene. However, brain metastasis and chest wall tumor relapse occurred. Considering insufficient improvement with gamma knife treatment for brain metastasis and combination chemotherapy (paclitaxel, carboplatin, and bevacizumab), pembrolizumab monotherapy and palliative irradiation therapy for chest metastases were started after brain tumor volume reduction using craniotomy. Brain edema and chest wall metastases markedly improved following a pseudoprogression of the brain edema accompanied by a performance status decline; this effect continued until 11 cycles of pembrolizumab administration.
ISSN:1759-7706
1759-7714

Similar Items